Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biomed Res Int. 2013;2013:297093. doi: 10.1155/2013/297093. Epub 2013 Nov 10.

Clinical evaluation of CyberKnife in the treatment of vestibular schwannomas.

Author information

  • 1Department of Radiation-Oncology, Taipei Medical University Wan-Fang Hospital, Taipei 110, Taiwan ; Department of Radiation-Oncology, Taipei Medical University Shuang-Ho Hospital, New Taipei City 23561, Taiwan.

Abstract

OBJECTIVE:

This study assessed the posttreatment tumor control and auditory function of vestibular schwannoma (VS) patients after CyberKnife (CK) and analyzed the possible prognostic factors of hearing loss.

METHODS:

We retrospectively studied 117 VS patients, with Gardner-Robertson (GR) classification grades I to IV, who underwent CK between 2006 and 2012. Data including radiosurgery treatment parameters, pre- and postoperative tumor size, and auditory function were collected and examined.

RESULTS:

With CK, 117 patients had excellent tumor control rates (99.1%), with a mean imaging followup of 61.1 months. Excluding 52 patients (GR III-IV pretreatment), 53 (81.5%) of the remaining 65 patients (initial GR I-II) maintained GR I or II hearing after CK, with a mean audiometric followup of 64.5 months. Twelve patients experienced hearing degradation (91.6% were GR II pretreatment); they appeared to have significantly larger tumor sizes, significantly smaller cochlear sizes, and higher prescribed cochlear doses, compared to the patients with preserved hearing.

CONCLUSION:

Our data showed that CK treatment provided an excellent tumor control rate and a comparable hearing preservation rate in VS patients. Patients with pretreatment GR II hearing levels, larger tumor volumes, smaller cochlear sizes, and higher prescribed cochlear doses may have poor hearing prognoses.

PMID:
24312910
[PubMed - indexed for MEDLINE]
PMCID:
PMC3842077
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk